Lanspro 30 Capsule contains Lansoprazole 30 mg, a proton pump inhibitor (PPI) used primarily for the treatment of acid-related gastrointestinal conditions. Lansoprazole acts by selectively inhibiting the H+/K+ ATPase enzyme system located in the gastric parietal cells, thereby suppressing gastric acid secretion. This reduction in acid production promotes healing of erosive esophagitis, peptic ulcers, and gastroesophageal reflux disease (GERD). Lanspro 30 is indicated for the management of duodenal ulcers, gastric ulcers, Zollinger-Ellison syndrome, and the eradication of Helicobacter pylori infection when used in combination with appropriate antibiotics. The capsule formulation ensures targeted release in the intestine, enhancing bioavailability and minimizing degradation by gastric acid. Lansoprazole is generally well tolerated, with common adverse effects including headache, abdominal pain, nausea, and diarrhea. Caution is advised in patients with hepatic impairment, and long-term use should be monitored due to potential risks such as vitamin B12 deficiency and increased susceptibility to gastrointestinal infections. Lanspro 30 should be administered as directed by a healthcare professional, typically before meals, to optimize therapeutic outcomes. Regular follow-up is recommended to assess efficacy and detect any adverse reactions.